Expectations trend
FY2027 · fiscal year ending 2027-12-31 · fmp
Serina Therapeutics Inc (SER)
AMEXHealth CareBiotechnologySnapshot 2026-11-04
$1.69-7.65%
Close 2026-11-04 · 1-day change
AMEXHealth CareBiotechnologySnapshot 2026-11-04
The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.
Next-FY EPS estimate change · 30 days
Matching fiscal periods, usable estimates and at least one analyst are required.
One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.
The calculation requires same-period, same-provider snapshots, positive EPS, at least one analyst and a baseline within three days of the requested lookback.
The EPS and P/E reference is not available for SER yet.
| Measure / period | Management expectations | Analyst expectations |
|---|
Management figures unavailable.
Current consensus figures unavailable.
Three published thesis conditions, with dated milestones shown separately.
| Key Factor | Why It Matters | Current Status | Break Condition | Latest Evidence |
|---|---|---|---|---|
resolve NYSE American minimum stockholders' equity non-compliance | The company is working to fix NYSE compliance and improve finances. | Improving | NYSE compliance issues remain unresolved past FY26 | Qualitative condition This condition has no defined numerical measure. Nov 4, 2026Last status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Compare these dated observations with the operating requirements above
FY2027 · fiscal year ending 2027-12-31 · fmp
The evidence, the remaining questions, and what comes next
No recovery evidence is reported in the available driver assessments.
Nov 12, 2026
Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.
Review earningsObserved price history; separate from operating scenarios
The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.
This is speculative clinical-stage growth, not an established earnings compounder. The multi-year view is on watch: SER has advanced its clinical work and strengthened its cash position, while recent performance remains weak and management execution is volatile.
The valuation model suggests SER trades at a premium to peers, with optionality as the main source of valuation divergence. Its priced-in tag is justified and fragility is low, but model confidence is low and the expectations gap is negative, so the valuation signal is uncertain.
Near term, the elevated risk of an earnings miss and the recent earnings miss point to continued uncertainty. Operating expenses and net loss rose from the first to the second quarter of 2026, while cash remained strong; enrollment and dosing in Cohort 1 finished ahead of guidance, and the study advanced to Cohort 2. Top-line data are planned for H1 2027, so clinical progress matters more to the multi-year thesis than near-term earnings.
The key company-level test is whether SER continues advancing SER-252 and delivers the planned data, while keeping enough financial support for development. A guidance cut would add pressure, and a weaker jobs trend could weigh on cyclical names; continued strength from major Healthcare companies could support sector momentum. The evidence on the announced agreement and capital-allocation event is limited, so their effect on the thesis is unclear.
Over the next 1 to 3 years, the thesis rests on clinical execution and the value of the POZ Platform, balanced against losses, high risk, and weak recent performance. The evidence is mixed, and confidence remains limited. Not investment advice.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
| A primary condition in Serina Therapeutics Inc's published investment case. The stated target is net loss narrows from -$6.9M in 2026-Q1 to less than -$3M by FY26 end. |
| Improving |
| net loss remains at or worsens beyond -$6.9M by FY26 end |
Net income: $-6.356M FY2026-Q2; GAAP. Published target: net loss narrows from -$6.9M in 2026-Q1 to less than -$3M by FY26 end. Annual target cannot be compared with a quarterly or TTM observation. Aug 13, 2026-6,356,000 USD · source valueLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
raise capital to support operations and pipeline development | A supporting condition in Serina Therapeutics Inc's published investment case. The stated target is successful capital raises sufficient to fund operations through FY26. | Intact | no material funding secured by end of FY26 | Capital raise secured (Aug 2026) Serina entered a definitive agreement with Roth Principal Investments on Aug 21, 2026, to issue common stock to accredited investors. Nov 4, 2026Last status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.
$-1.57 → $-1.15 · observed estimates
Unavailable → Unavailable · observed estimates
One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.
| Snapshot | EPS | Revenue | EPS / revenue analysts |
|---|---|---|---|
| 2026-07-24 | $-1.57 | Unavailable | 1 / 0 |
| 2026-07-25 | $-1.57 | Unavailable | 1 / 0 |
| 2026-07-26 | $-1.57 | Unavailable | 1 / 0 |
| 2026-07-27 | $-1.57 | Unavailable | 1 / 0 |
| 2026-07-28 | $-1.05 | $0 | 1 / 2 |
| 2026-07-29 | $-1.57 | Unavailable | 1 / 0 |
| 2026-07-30 | $-1.05 | $0 | 1 / 2 |
| 2026-07-31 | $-1.57 | Unavailable | 1 / 0 |
| 2026-08-01 | $-1.57 | Unavailable | 1 / 0 |
| 2026-08-02 | $-1.05 | $0 | 1 / 2 |
| 2026-08-03 | $-1.05 | $0 | 1 / 2 |
| 2026-08-04 | $-1.57 | Unavailable | 1 / 0 |
| 2026-08-05 | $-1.05 | $0 | 1 / 2 |
| 2026-08-06 | $-1.05 | $0 | 1 / 2 |
| 2026-08-08 | $-1.05 | $0 | 1 / 2 |
| 2026-08-09 | $-1.05 | $0 | 1 / 2 |
| 2026-08-10 | $-1.05 | $0 | 1 / 2 |
| 2026-08-12 | $-1.57 | Unavailable | 1 / 0 |
| 2026-08-13 | $-1.57 | Unavailable | 1 / 0 |
| 2026-08-14 | $-1.57 | Unavailable | 1 / 0 |
| 2026-08-15 | $-1.57 | Unavailable | 1 / 0 |
| 2026-08-16 | $-1.57 | Unavailable | 1 / 0 |
| 2026-08-17 | $-1.57 | Unavailable | 1 / 0 |
| 2026-08-18 | $-1.57 | Unavailable | 1 / 0 |
| 2026-08-19 | $-1.57 | Unavailable | 1 / 0 |
| 2026-08-20 | $-1.43 | Unavailable | 1 / 0 |
| 2026-08-21 | $-1.16 | Unavailable | 1 / 0 |
| 2026-08-22 | $-1.16 | Unavailable | 1 / 0 |
| 2026-08-23 | $-1.16 | Unavailable | 1 / 0 |
| 2026-08-24 | $-1.16 | Unavailable | 1 / 0 |
| 2026-08-25 | $-1.16 | Unavailable | 1 / 0 |
| 2026-08-26 | $-1.16 | Unavailable | 1 / 0 |
| 2026-08-27 | $-1.16 | Unavailable | 1 / 0 |
| 2026-08-28 | $-1.16 | Unavailable | 1 / 0 |
| 2026-08-29 | $-1.16 | Unavailable | 1 / 0 |
| 2026-08-30 | $-1.16 | Unavailable | 1 / 0 |
| 2026-08-31 | $-1.16 | Unavailable | 1 / 0 |
| 2026-09-01 | $-1.16 | Unavailable | 1 / 0 |
| 2026-09-02 | $-1.16 | Unavailable | 1 / 0 |
| 2026-09-03 | $-1.16 | Unavailable | 1 / 0 |
| 2026-09-04 | $-1.16 | Unavailable | 1 / 0 |
| 2026-09-05 | $-1.16 | Unavailable | 1 / 0 |
| 2026-09-06 | $-1.16 | Unavailable | 1 / 0 |
| 2026-09-07 | $-1.16 | Unavailable | 1 / 0 |
| 2026-09-08 | $-1.16 | Unavailable | 1 / 0 |
| 2026-09-09 | $-1.16 | Unavailable | 1 / 0 |
| 2026-09-10 | $-1.16 | Unavailable | 1 / 0 |
| 2026-09-11 | $-1.15 | Unavailable | 1 / 0 |
| 2026-09-12 | $-1.15 | Unavailable | 1 / 0 |
| 2026-09-13 | $-1.15 | Unavailable | 1 / 0 |
| 2026-09-14 | $-1.15 | Unavailable | 1 / 0 |
| 2026-09-15 | $-1.15 | Unavailable | 1 / 0 |
| 2026-09-16 | $-1.15 | Unavailable | 1 / 0 |
| 2026-09-17 | $-1.15 | Unavailable | 1 / 0 |
| 2026-09-18 | $-1.15 | Unavailable | 1 / 0 |
| 2026-09-19 | $-1.15 | Unavailable | 1 / 0 |
| 2026-09-20 | $-1.15 | Unavailable | 1 / 0 |
| 2026-09-21 | $-1.15 | Unavailable | 1 / 0 |
| 2026-09-22 | $-1.15 | Unavailable | 1 / 0 |
| 2026-09-23 | $-1.15 | Unavailable | 1 / 0 |
| 2026-09-24 | $-1.15 | Unavailable | 1 / 0 |
| 2026-09-25 | $-1.15 | Unavailable | 2 / 0 |
| 2026-09-26 | $-1.15 | Unavailable | 2 / 0 |
| 2026-09-27 | $-1.15 | Unavailable | 2 / 0 |
| 2026-09-28 | $-1.15 | Unavailable | 2 / 0 |
| 2026-09-29 | $-1.15 | Unavailable | 2 / 0 |
| 2026-09-30 | $-1.15 | Unavailable | 2 / 0 |
| 2026-10-01 | $-1.15 | Unavailable | 2 / 0 |
| 2026-10-02 | $-1.15 | Unavailable | 2 / 0 |
| 2026-10-03 | $-1.15 | Unavailable | 2 / 0 |
| 2026-10-04 | $-1.15 | Unavailable | 2 / 0 |
| 2026-10-05 | $-1.15 | Unavailable | 2 / 0 |
| 2026-10-06 | $-1.15 | Unavailable | 2 / 0 |
| 2026-10-07 | $-1.15 | Unavailable | 2 / 0 |
| 2026-10-08 | $-1.15 | Unavailable | 2 / 0 |
| 2026-10-09 | $-1.15 | Unavailable | 2 / 0 |
| 2026-10-10 | $-1.15 | Unavailable | 2 / 0 |
| 2026-10-11 | $-1.15 | Unavailable | 2 / 0 |
| 2026-10-12 | $-1.15 | Unavailable | 2 / 0 |
| 2026-10-13 | $-1.15 | Unavailable | 2 / 0 |
| 2026-10-14 | $-1.15 | Unavailable | 2 / 0 |
| 2026-10-15 | $-1.15 | Unavailable | 2 / 0 |
| 2026-10-16 | $-1.15 | Unavailable | 2 / 0 |
| 2026-10-17 | $-1.15 | Unavailable | 2 / 0 |
| 2026-10-18 | $-1.15 | Unavailable | 2 / 0 |
| 2026-10-19 | $-1.15 | Unavailable | 2 / 0 |
| 2026-10-20 | $-1.15 | Unavailable | 2 / 0 |
| 2026-10-21 | $-1.15 | Unavailable | 2 / 0 |
| 2026-10-22 | $-1.15 | Unavailable | 2 / 0 |
| 2026-10-23 | $-1.15 | Unavailable | 2 / 0 |
| 2026-10-24 | $-1.15 | Unavailable | 2 / 0 |
| 2026-10-25 | $-1.15 | Unavailable | 2 / 0 |
| 2026-10-26 | $-1.15 | Unavailable | 2 / 0 |
| 2026-10-27 | $-1.15 | Unavailable | 2 / 0 |
| 2026-10-28 | $-1.15 | Unavailable | 2 / 0 |
| 2026-10-29 | $-1.15 | Unavailable | 2 / 0 |
| 2026-10-30 | $-1.15 | Unavailable | 2 / 0 |
| 2026-10-31 | $-1.15 | Unavailable | 2 / 0 |
| 2026-11-01 | $-1.15 | Unavailable | 2 / 0 |
| 2026-11-02 | $-1.15 | Unavailable | 2 / 0 |
| 2026-11-03 | $-1.15 | Unavailable | 2 / 0 |
| 2026-11-04 | $-1.15 | Unavailable | 2 / 0 |
Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.
Latest: 2 Buy / Strong Buy · 0 Hold · 0 Sell / Strong Sell
Recent actions · Oct 6–Nov 4 · 1 recorded
Individual price-target observations are unavailable.
0 raises · 0 cuts · 0 unchanged · 0 without a comparable prior
Oct 6, 2026–Nov 4, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.
2 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.
The dated weekly assessment and its assumptions are available in Read detailed Outlook.